Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors
Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors
复制标题
DOI：
10.21873/anticanres.13716
复制
发表时间：
2019-09-01
影响因子：
2
通讯作者：
Wada, Satoshi
中科院分区：
文献类型：
--
作者：
Ando, Kiyohiro;Hamada, Kazuyuki;Wada, Satoshi
背景/目的：通过免疫检查点抑制剂（ICI）进行癌症免疫治疗是一种有前途的治疗各种癌症的策略。在ICI中，抗程序性细胞死亡蛋白-1（PD 1）和抗程序性死亡配体1（PD-L1）抗体已显示出显著的临床益处。本研究旨在探讨患者血清可溶性PD-L1（sPD-L1）水平的功能和临床意义。材料与方法：共21例患者，11例NSCLC，9例胃癌和1例膀胱癌，接受抗PD-1治疗，通过ELISA分析在诊断和治疗后评估sPD-L1浓度。结果如下：接受ICIs治疗的患者治疗前sPD-L1水平与这些患者的总生存期无显著相关性（r=0.3394，p=0.1323）。在接受4个周期治疗的患者中，血浆sPD-L1水平的降低与肿瘤消退显著相关（p
Background/Aim: Cancer immune therapy by immune checkpoint inhibitors (ICIs) is a promising therapeutic strategy for various cancer types. Among ICIs, anti-programmed cell death protein-1 (PD1) and anti-programmed death-ligand 1 (PD-L1) antibodies have shown a remarkable clinical benefit. The present study aimed to address the functional and clinical significance of serum levels of soluble PD-L1 (sPD-L1) in patients. Materials and Methods: A total of 21 patients, 11 with NSCLC, nine with gastric cancer and one with bladder cancer, who underwent anti-PD-1 therapy were evaluated for sPD-L1 concentration by ELISA analyses at diagnosis and after treatment. Results: Pretreatment levels of sPD-L1 in patients who received ICIs were not remarkably correlated with the overall survival of these patients (r=0.3394, p=0.1323). Reduction of plasma sPD-L1 level was significantly correlated with tumor regression in patients administered four cycles of treatment (p